CDK4/6 Inhibitor Related AEs

CE / CME

Managing AEs With CDK4/6 Inhibitors to Promote Adherence and Persistence to Oral Therapy in Your Practice

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: December 06, 2024

Expiration: August 09, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 55-year-old woman was recently diagnosed with metastatic ER+/HER2- breast cancer 2 years after completing adjuvant endocrine therapy with asymptomatic bone-only disease. Four weeks ago, she began receiving first-line letrozole and ribociclib (600 mg daily, 3 wk on, 1 wk off). Laboratory monitoring at C2D1 shows LFTs are now 5x ULN (grade 3 hepatotoxicity); she is otherwise asymptomatic; ECG is stable.

Which of the following is optimal management for this patient’s grade 3 LFT?